Koyfin Home > Directory > Health Care > Acceleron Pharma > Repurchase of Common Stock

Acceleron Pharma Repurchase of Common Stock Chart (XLRN)

Acceleron Pharma annual/quarterly Repurchase of Common Stock from 2017 to 2019.
  • Acceleron Pharma Repurchase of Common Stock for the quarter ending December 12, 2019 was $-1m a 89.28% decrease of -1m year over year
  • Acceleron Pharma Repurchase of Common Stock for the last 12 months ending June 06, 2020 was $-1m a 8.85% decrease of 0m year over year
  • Acceleron Pharma Annual Repurchase of Common Stock for 2019 was $-1m a 8.85% decrease of 0m from 2018
  • Acceleron Pharma Annual Repurchase of Common Stock for 2018 was $-1m a 69.08% decrease of -1m from 2017
  • Acceleron Pharma Annual Repurchase of Common Stock for 2017 was $0m
Other Cash Flow Metrics:
  • Acceleron Pharma Cash Flow from Operations for the quarter ending December 12, 2018 was $-29m a 19.28% decrease of -6m year over year
  • Acceleron Pharma Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-41m a 62.43% decrease of -26m year over year
  • Acceleron Pharma Total Revenue for the quarter ending September 09, 2018 was $3m a -13.72% decrease of 0m year over year
View Chart On Koyfin

Quarterly XLRN Repurchase of Common Stock Data

12/2019$-1m
12/2018$-1m
12/2017$0m
09/2017$0m
06/2017$0m
03/2017$0m

Annual XLRN Repurchase of Common Stock Data

2019$-1m
2018$-1m
2017$0m